头孢拉宗钠不同剂量单次静滴后在健康人血清的杀菌活性  

Serum bactericidal activity of different single doses of intravenous cefbuperazone sodium in Chinese healthy volunteers

作　　者：白艳[1] 王瑾[1] 梁蓓蓓[1] 白楠[1] 曹江[1] 蔡芸[1] 韩宇阳[1] 裴广胜[1] 王睿[1] 

机构地区：[1]中国人民解放军总医院药物临床研究中心,北京100853

出　　处：《中国临床药理学杂志》2011年第11期822-826,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的研究单次静滴不同剂量头孢拉宗钠在中国健康受试者的血清杀菌活性(SBA)。方法用微量稀释法,测定14株产超广谱β内酰胺酶(ESBLs)的肺炎克雷伯菌和大肠埃希菌与7株甲氧西林敏感金黄色葡萄球菌(MSSA)的最低抑菌浓度(MIC);12名健康受试者单次静滴不同剂量头孢拉宗钠,于1 h(峰时),6,8 h与12 h(谷时)采血,用微量肉汤稀释法测定SBA,并进行统计分析。结果头孢拉宗钠对临床常见3种致病菌均敏感;对产ESBLs的肺炎克雷伯菌、大肠埃希菌和MSSA,不同剂量头孢拉宗钠对同一种致病菌的峰时SBA中位数比较,差异有统计学意义(P<0.05);单次静滴不同剂量头孢拉宗钠峰时SBA≥1∶8的百分率进行卡方检验,产ESBLs的肺炎克雷伯菌、大肠埃希菌1 g/1 h组和3 g/1 h组间,差异有统计学意义(P<0.05);3个剂量对MSSA组间比较差异有统计学意义(P<0.05)。结论相较对MSSA,注射用头孢拉宗钠对产超广谱β内酰胺酶(ESBLs)的肺炎克雷伯菌、大肠埃希菌具有更强的体内杀菌活性,从而预测其有较好的临床疗效。Objective To compare the serum bactericidal activity（SBA） of different single doses of intravenous cefbuperazone sodium（CBPZ） in Chinese healthy volunteers and to evaluate antibacterial activity in vivo of CBPZ against producing extended spectrum β-lactamases（ESBLs） in Klebsiellapneumoniae,Escherichia coli and methicillin resistant Staphylococcus aureas（MSSA）.Methods Minimal inhibitory concentration（MIC） of CBPZ against 14 strains ESBLs positive Klebsiellapneumoniae and Escherichia coli,and 7 strains of MSSA was determined by microdilution method.Twelve healthy male and female volunteers were given three single doses of intravenous CBPZ respectively and blood sample were collected at the 1,6,8,12 h after infusion.SBA was determined by microdilution method.Results The MIC of CBPZ against for the study isolates were sensitivity.The peaks SBA of CBPZ against ESBLs positive Klebsiellapneumoniae and Escherichia coli,and MSSA among three injection doses,significant differences were observed（P0.05）;There was significant difference between 3 g/1 h and 1 g/1 h of CBPZ against ESBLs positive Klebsiellapneumoniae and Escherichia coli of the percentage of peak SBA≥1∶8（P0.05）,and there was significant differences among three doses of CBPZ against MSSA（P0.05）. Conclusion In vivo the SBA of different single doses of intravenous CBPZ against ESBLs positive Klebsiellapneumoniae and Escherichia coli shown to be stronger than that of CBPZ against MSSA in Chinese healthy volunteers,which predict a better clinical efficacy.

关 键 词：头孢拉宗钠 超广谱Β内酰胺酶 血清杀菌活性 

分 类 号：R978.11[医药卫生—药品] R515[医药卫生—药学]